Your browser doesn't support javascript.
loading
Functioning and neurocognition in very early and early-life onset bipolar disorders: the moderating role of bipolar disorder type.
Sleurs, D; Speranza, M; Etain, B; Aouizerate, B; Aubin, V; Bellivier, F; Belzeaux, R; Carminati, M; Courtet, P; Dubertret, C; Fredembach, B; Haffen, E; Groppi, F; Laurent, P; Leboyer, M; Llorca, P M; Olié, E; Polosan, M; Schwan, R; Weill, D; Passerieux, C; Roux, P.
Affiliation
  • Sleurs D; Fondation FondaMental, Créteil, France. david.sleurs@aphp.fr.
  • Speranza M; AP-HP, Groupe Hospitalo-Universitaire AP-HP Nord, DMU ESPRIT, Service de Psychiatrie Et Addictologie, Hopital Louis Mourier, 178 Rue Des Renouillers, 92700, Colombes, France. david.sleurs@aphp.fr.
  • Etain B; Inserm U1266, Faculté de Médecine, Université Paris Cité, Paris, France. david.sleurs@aphp.fr.
  • Aouizerate B; Fondation FondaMental, Créteil, France.
  • Aubin V; Centre Hospitalier de Versailles, Service Universitaire de Psychiatrie de L'Enfant Et de L'Adolescent, Le Chesnay, France.
  • Bellivier F; Université Paris-Saclay, Paris, France.
  • Belzeaux R; Université de Versailles Saint-Quentin-En-Yvelines, Versailles, France.
  • Carminati M; DisAP-DevPsy-CESP, INSERM UMR1018, Villejuif, France.
  • Courtet P; Fondation FondaMental, Créteil, France.
  • Dubertret C; AP-HP, Groupe Hospitalo-Universitaire AP-HP Nord, DMU Neurosciences, Département de Psychiatrie Et de Médecine Addictologique, Hôpital Fernand Widal, Paris, France.
  • Fredembach B; INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Université Paris Cité, Paris, France.
  • Haffen E; Fondation FondaMental, Créteil, France.
  • Groppi F; Laboratoire NutriNeuro (UMR INRA 1286), Centre Hospitalier Charles Perrens, Université de Bordeaux, Bordeaux, France.
  • Laurent P; Fondation FondaMental, Créteil, France.
  • Leboyer M; Pôle de Psychiatrie, Centre Hospitalier Princesse Grace, Monaco, France.
  • Llorca PM; Fondation FondaMental, Créteil, France.
  • Olié E; AP-HP, Groupe Hospitalo-Universitaire AP-HP Nord, DMU Neurosciences, Département de Psychiatrie Et de Médecine Addictologique, Hôpital Fernand Widal, Paris, France.
  • Polosan M; INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Université Paris Cité, Paris, France.
  • Schwan R; Fondation FondaMental, Créteil, France.
  • Weill D; Pôle de Psychiatrie, Assistance Publique Hôpitaux de Marseille, Marseille, France.
  • Passerieux C; Fondation FondaMental, Créteil, France.
  • Roux P; AP-HP, Groupe Hospitalo-Universitaire AP-HP Nord, DMU Neurosciences, Département de Psychiatrie Et de Médecine Addictologique, Hôpital Fernand Widal, Paris, France.
Article in En | MEDLINE | ID: mdl-38702455
ABSTRACT
Defining homogeneous subgroups of bipolar disorder (BD) is a major goal in personalized psychiatry and research. According to the neurodevelopmental theory, age at onset may be a key variable. As potential trait markers of neurodevelopment, cognitive and functional impairment should be greater in the early form of the disease, particularly type 1 BD (BD I). The age at onset was assessed in a multicenter, observational sample of 4190 outpatients with BD. We used a battery of neuropsychological tests to assess six domains of cognition. Functioning was measured using the Functioning Assessment Short Test (FAST). We studied the potential moderation of the type of BD on the associations between the age at onset and cognitive and functioning in a subsample of 2072 euthymic participants, controlling for potential clinical and socio-demographic covariates. Multivariable analyses showed cognition to not be impaired in individuals with early (21-30 years) and very early-life (before 14 years) onset of BD. Functioning was equivalent between individuals with early and midlife-onset of BD II and NOS but better for individuals with early onset of BD I. In contrast, functioning was not worse in individuals with very early-onset BD I but worse in those with very early-onset BD II and NOS. Early-life onset BDs were not characterized by poorer cognition and functioning. Our results do not support the neurodevelopmental view that a worse cognitive prognosis characterizes early-life onset BD. This study suggests that functional remediation may be prioritized for individuals with midlife-onset BD I and very early life onset BD 2 and NOS.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur Child Adolesc Psychiatry Journal subject: PEDIATRIA / PSIQUIATRIA Year: 2024 Document type: Article Affiliation country: Francia

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur Child Adolesc Psychiatry Journal subject: PEDIATRIA / PSIQUIATRIA Year: 2024 Document type: Article Affiliation country: Francia